The gift will support the development of AI-driven patient-centered solutions focused on early detection of the disease. To that end, a multidisciplinary team will build algorithms that make it possible to systematically identify people at high risk, leveraging decades of well-characterized clinical data; develop a machine-learning algorithm for precise, image-based identification of the cancer in its early stages as well as advanced precancerous lesions; discover and validate new molecular biomarkers; and establish a collaborative clinical care model for people at high risk of developing the disease.
According to the Mayo Clinic, more than half of all pancreatic cancer patients are diagnosed at a late stage when the disease has spread beyond the pancreas and treatment is far more challenging, whereas those who are diagnosed at an early stage can survive five or more years after diagnosis.
"Cancer does not discriminate by age, race, or status, and the work of medical researchers at Mayo Clinic is vital to improving the health of our communities," said Centene chair, president, and CEO Michael F. Neidorff. "Together, we can address the unique needs of individuals impacted by pancreatic cancer."
(Image credit: Mayo Clinic)